



62 JUN 3 1996 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:  
Philippe Pouletty  
Serial No. 08/630,383

Filed: 11 April 1996

For: *Cytomodulating Conjugates of Members of Specific Binding Pairs*

Group Art Unit: Not yet assigned

Examiner: Not yet assigned

Attorney Docket No. A-55320-2/BIR  
SANG-013-2

CERTIFICATE OF MAILING  
I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231 on 05-29-99.

Signed   
Lydia E. Epps

#### INFORMATION DISCLOSURE STATEMENT

The Commissioner of Patent and Trademarks  
Washington D.C. 20231

Sir:

This Information Disclosure Statement is being submitted for the previously filed application identified above.

The Applicant hereby submits patents, publications, or other information of which they are aware, which they believe may be material to the examination of the above referenced application and in respect to which there may be a duty to disclose in accordance with 37 C.F.R. §1.56.

The disclosure contained herein is not intended to constitute an admission that any patent, publication, or other information referred to is "prior art" for this invention unless specifically designated as such.

In accordance with 37 C.F.R. §1.97 (b), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined by 37 C.F.R. §1.56 exists.

#### LISTING AND EXPLANATION OF INFORMATION ITEMS

A list of patents and publications is set forth here and on the attached Form PTO-1449. The list is divided into U.S. Patents, Foreign Published Applications or Patents, and other printed publications so that document identification data prescribed in 37 C.F.R. §1.98 may be conveniently set forth.

BEST AVAILABLE COPY

U.S. Patents:

The Applicant is aware of the following U.S. patents which they believe may be material to the examination of the referenced application.

1. U.S. Patent No. 4,971,792

Foreign published Applications or Patents:

The Applicant is aware of the following foreign published applications or patents which they believe may be material to the examination of the referenced application.

1. European Patent Application 0 324 625
2. European Patent Application 0 305 967
3. European Patent Application 0 367 166
4. European Patent Application 0 396 387
5. PCT Patent Application WO 91/01146
6. PCT Patent Application WO 92/03569
7. PCT Patent Application WO 91/01146

Other Printed publications:

The Applicant is aware of the following printed publications which may be material to the examination of the referenced application:

1. H. Liu et al., "Conventional Antigen and Superantigen May Be Coupled to Distinct and Cooperative T-Cell Activation Pathways," *PNAS* (1991), 88:8705-8709.
2. M. Kotb et al., "Accessory Cell-Independent Stimulation of Human T Cells by Streptococcal M-Protein Superantigen," *J.I.* (1990), 145:1332-1336.
3. Kaplan, "Flow Rate Dependence of In Vitro Removal of Anti-A and Anti-B Antibodies by Immunoabsorbents with Synthetic Oligosaccharides Representing Blood Group Substances," *The Intl. J. of Artificial Organs* (1989), 12:799-804.
4. Junghans et al., "Anti-Tac-H, A Humanized Antibody to the Interleukin 2 Receptor with New Features for Immunotherapy in Malignant and Immune Disorders," *Cancer Research* 50 (March 1990), 1495-1502.
5. Schroeder et al., "Antimurine Antibody Formation Following OKT3 Therapy," *Transplantation* (Jan. 1990), 49:48-51.
6. Lando et al., "Co-Stimulation with B7 and Targeted Superantigen is Required for MHC Class II-Independent T-Cell Proliferation but Not Cytotoxicity," *Immunology* (1993), 80:236-241.
7. Green, "The ABO, Lewis and Related Blood Group Antigens; A Review of Structure and Biosynthesis," *FEMS Microbiology Immunology* 47 (1989), 321-330.

8. Ocho et al., "In Vivo Tumor Immunotherapy by a Bacterial Superantigen," *The J. of Immunology* (Sept. 1993), 131:3180-3186.

9. Lorberboum-Galski et al., "Cytotoxic Activity of an Interleukin 2-Pseudomonas Exotoxin Chimeric Protein Produced in Escherichia Coli," *PNAS USA* (March 1988), 1922-1926.

10. Batra et al., "Anti-Tac (Fv)-PE40, A Single Chain Antibody Pseudomonas Fusion Protein Directed at Interleukin 2 Receptor Bearing Cells," *The J. of Biological Chemistry* (Sept. 1990), 265:15198-15202.

11. Garrido et al., "Targeting Human T-Lymphocytes with Bispecific Antibodies to React Against Human Ovarian Carcinoma Cells Growing in Nu/Nu Mice," *Cancer Research* 50 (July 1990), 4227-4232.

12. Pullen et al., "Identification of the Region of T Cell Receptor  $\beta$  Chain That Interacts with the Self-Superantigen Mls-1 $^a$ ," *Cell* (June 1990), 61:1365-1374.

13. Dohlstein et al., "Monoclonal Antibody-Targeted Superantigens: A Different Class of Anti-Tumor Agents," *PNAS USA* (Oct. 1991), 88:9287-9291.

Copies:

Copies of the listed references under "U.S. Patents", "Foreign published Applications or Patents" and "Other Printed Publications" above, were previously submitted with, or cited in, U.S. Application Serial No. 07/690,530 filed 23 April 1991, which is the grandparent of the above captioned application and in U.S. Application Serial No. 08/254,299 filed 6 June 1994 the parent of the above captioned application.

The Commissioner is hereby authorized to charge any additional fees or credit any overpayment to Deposit Account No. 06-1300 (order no. A-55320-2/BIR). Two duplicate copies of this page are enclosed.

Respectfully submitted,

FLEHR, HOHBACH, TEST  
ALBRITTON & HERBERT

By:

  
Bret E. Field  
Registration No. 37,620

4 Embarcadero Center, Suite 3400  
San Francisco, CA 94111-4187  
(415) 781-1989

(62862)

BEST AVAILABLE COPY